Natera — Third Quarter 2026 Earnings Summary

Natera reported third-quarter 2026 total revenues of $794.0 million, representing a 34.1% increase from the same period in 2025, driven by higher test volumes and average selling price improvements. The company processed approximately 1.09 million tests during the quarter, including a 60.9% year-over-year growth in oncology tests, while achieving a gross margin of 64.7%. Natera reported a net loss of $59.9 million for the quarter, or $0.42 per diluted share, compared to a net loss of $87.5 million in the prior year period. Additionally, the company raised its full-year 2026 revenue guidance to a midpoint of $3.02 billion and maintained a cash position of approximately $1.1 billion as of September 30, 2026.